Avacopan for anti‑neutrophil cytoplasmic antibody‑associated vasculitis: a meta‑analysis of efficacy and safety

Read full text Summarise with VIRAT
Authors: Yang Hong, Li Ying
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ObjectiveTo systematically evaluate the efficacy and safety of avacopan in patients with anti‑neutrophil cytoplasmic antibody‑associated vasculitis(AAV).MethodsWe performed a comprehensive literature search of Embase, PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang, and VIP from database inception to June 2025 for randomized controlled trials (RCTs) and cohort studies assessing avacopan in AAV. Data were pooled using RevMan 5.4.ResultsTen studies (3 RCTs and 7 cohort studies) comprising 727 patients were included. In RCTs, avacopan did not significantly affect overall remission rate compared with control (RR=1.03; 95%CI:0.90-1.18; P=0.69), but it significantly improved sustained remission rate (RR=1.22; 95%CI:1.02⁃1.45; P=0.03). Cohort studies showed a lower relapse rate with avacopan versus control (RR=0.49; 95%CI:0.30-0.79; P=0.004). Single‑arm pooled analyses indicated high event rates for remission (88%; 95%CI:0.82-0.92) and sustained remission (87%; 95%CI:0.78-0.93), with a low pooled relapse proportion (7%; 95%CI:0.04-0.12). Renal outcomes favored avacopan: RCTs showed a small but statistically significant improvement in eGFR [mL·min-1·(1.73 m2)-1] change from baseline to endpoint (MD=2.76; 95%CI:0.21-5.30; P=0.03). Real‑world cohort data demonstrated clinically meaningful eGFR gains at 6 months (MD=9.40; 95%CI:0.44-18.37; P=0.04) and 12 months (MD=13.88; 95%CI:8.47-19.28; P

Fields of Study & Subjects

Vasculitis and related conditions Complement system in diseases Systemic Lupus Erythematosus Research

Publication details

Journal / source
DOAJ (DOAJ: Directory of Open Access Journals)
Publication date
1 March 2026
Language
ZH